MAIA Biotechnology Leadership Increases Ownership Stakes in Company

CHICAGO, Sept. 15, 2026 /CourierPR/ -- MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, has seen its leadership team take a significant step in boosting their confidence in the company’s future. Board member Ramiro Guerrero, JD, LL.M., and Founder and CEO Vlad Vitoc, M.D., have both increased their ownership stakes in the company through open market purchases.

Guerrero, who is a long-standing member of the board, purchased 185,078 shares of MAIA common stock between August 20, 2026, and September 10, 2026, at an average price of $1.36 per share. This acquisition totals approximately $252,284. Vitoc, the CEO, also added to his holdings by acquiring 73,000 shares on September 14, 2026, at an average price of $1.37 per share.

The actions of the leadership team reflect their belief in the company’s scientific approach and its potential for commercial success.

MAIA’s ongoing pivotal Phase 3 trial, THIO-104, evaluates ateganosine sequenced with checkpoint inhibitor cemiplimab versus investigator’s choice in third-line non-small cell lung cancer (NSCLC). The trial is seen as a critical step in the company’s development, with statistical assessments suggesting a high probability of technical success. Positive initial efficacy data from the ongoing Phase 2 THIO-101 clinical trial expansion, Part C, showed a disease control rate (DCR) of 90.5% in the efficacy evaluable population who had at least one tumor scan after starting treatment.

As of September 14, 2026, MAIA’s directors and officers hold a 21.34% stake in the company. The company’s lead program, ateganosine (THIO), is a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activate both innate (cGAS/STING) and adaptive (T-cell) immune responses.

The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by inducing cancer type-specific immune memory. Ateganosine is currently being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

MAIA Biotechnology, Inc., continues to focus on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company is optimistic about the potential of its lead program and the ongoing clinical trials.